IRVINE, CA / ACCESSWIRE / February 2, 2023 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 second quarter ended December 31, 2022. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2023 with the Securities and Exchange Commission today.
Quarter Ended December 31, 2022
Net sales for the three months ended December 31, 2022 increased $1.1 million, or 11%, to $11.3 million from $10.2 million for the three months ended December 31, 2021, due primarily to sales of the orthopedic surgical handpiece that we sell to our largest customer coupled with increased repair revenue of that same handpiece.
Gross profit for the three months ended December 31, 2022 decreased $781,000, or 23%, to $2.6 million from $3.4 million for the same period in fiscal 2022, due to continuing price increases for components, especially chips for our printed circuit board assemblies, as well higher repair costs for the surgical handpiece that we sell to our largest customer. As previously disclosed, beginning in fiscal 2023 and continuing through the end of the second quarter of fiscal 2023, we began implementing a customer upgrade request for our largest customer. We have proceeded in good faith to upgrade all units returned for repair to the newest release of the handpiece while we continue to negotiate with this customer to obtain additional compensation for these more costly upgraded repairs.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2022 decreased $316,000, or 18%, to $1.5 million compared to $1.8 million in the prior fiscal year's corresponding quarter, reflecting in part the higher number of billable engineering projects in the current fiscal quarter compared to the same period in the prior fiscal year and reduced general and administrative expenses mostly due to declining non-cash stock compensation expense.
Net income for the quarter ended December 31, 2022 was $879,000, or $0.24 per diluted share, compared to $925,000, or $0.25 per diluted share, for the corresponding quarter in fiscal 2022.
Six Months Ended December 31, 2022
Net sales for the six months ended December 31, 2022 increased $2.2 million, or 11%, to $22.4 million from $20.2 million for the six months ended December 31, 2021, due primarily to increased repair revenue from the orthopedic surgical handpiece that we sell to our largest customer and increased non-recurring engineering and proto-type revenue.
Gross profitfor the six months ended December 31, 2022decreased $1.3 million, or 18%, compared to the same period in fiscal 2022 due to the increased costs incurred in the repairs of the surgical handpiece we sell to our largest customer as described above, continuing component price increases, and higher cost structures in our machine shop, assembly, materials, and quality departments.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2022 decreased $420,000, or 11%, to $3.5 million compared to $3.9 million in the prior fiscal year's corresponding period.
Net income for the six months ended December 31, 2022 and 2021 remained flat at $2.0 million, or $0.53 per diluted share.
CEO Comments
Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our second quarter and year-to-date results especially considering the challenging environment facing businesses today." Mr. Van Kirk continued, "We are excited to begin operations in the Franklin facility this fiscal quarter and we remain positive that the building will allow for our continued expected growth."
About Pro-Dex, Inc.:
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance (including, but not limited to, the anticipated commencement of operations in the Franklin facility and expected future growth), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
(tables follow)
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)
| December 31, 2022 | June 30, 2022 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 382 | $ | 849 | ||||
Investments | 1,134 | 755 | ||||||
Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at December 31, 2022 and at June 30, 2022, respectively | 12,195 | 15,384 | ||||||
Deferred costs | 877 | 710 | ||||||
Inventory | 15,135 | 12,678 | ||||||
Prepaid expenses and other current assets | 1,664 | 790 | ||||||
Total current assets | 31,387 | 31,166 | ||||||
Land and building, net | 6,296 | 6,343 | ||||||
Equipment and leasehold improvements, net. | 5,203 | 4,833 | ||||||
Right-of-use asset, net | 2,063 | 2,248 | ||||||
Intangibles, net | 98 | 118 | ||||||
Deferred income taxes, net | 764 | 797 | ||||||
Investments | 1,726 | 1,779 | ||||||
Other assets | 42 | 42 | ||||||
Total assets | $ | 47,579 | $ | 47,326 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,364 | $ | 3,761 | ||||
Accrued expenses | 3,314 | 2,751 | ||||||
Income taxes payable | 1,026 | 544 | ||||||
Deferred revenue | 851 | 1,013 | ||||||
Notes payable | 3,110 | 3,285 | ||||||
Total current liabilities | 11,665 | 11,354 | ||||||
Lease liability, net of current portion | 1,850 | 2,054 | ||||||
Notes payable, net of current portion | 9,590 | 10,250 | ||||||
Total non-current liabilities | 11,440 | 12,304 | ||||||
Total liabilities | 23,105 | 23,658 | ||||||
Shareholders' equity: | ||||||||
Common shares; no par value; 50,000,000 shares authorized; 3,553,929 and 3,596,131 shares issued and outstanding at December 31, 2022 and June 30, 2022, respectively | 6,533 | 7,682 | ||||||
Retained earnings | 17,941 | 15,986 | ||||||
Total shareholders' equity | 24,474 | 23,668 | ||||||
Total liabilities and shareholders' equity | $ | 47,579 | $ | 47,326 | ||||
PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
| Three Months Ended December 31, | Six Months Ended December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Net sales | $ | 11,282 | $ | 10,173 | $ | 22,369 | $ | 20,161 | ||||||||
Cost of sales | 8,659 | 6,769 | 16,791 | 13,329 | ||||||||||||
Gross profit | 2,623 | 3,404 | 5,578 | 6,832 | ||||||||||||
Operating expenses: Selling expenses | 68 | 22 | 122 | 59 | ||||||||||||
General and administrative expenses | 951 | 1,165 | 1,975 | 2,257 | ||||||||||||
Research and development costs | 467 | 615 | 1,395 | 1,596 | ||||||||||||
Total operating expenses | 1,486 | 1,802 | 3,492 | 3,912 | ||||||||||||
Operating income | 1,137 | 1,602 | 2,086 | 2,920 | ||||||||||||
Interest expense | (128 | ) | (117 | ) | (258 | ) | (237 | ) | ||||||||
Unrealized gain (loss) on marketable equity investments | 158 | (300 | ) | 408 | (152 | ) | ||||||||||
Interest and other income | 7 | 25 | 225 | 49 | ||||||||||||
Gain on sale of investments | - | - | 7 | - | ||||||||||||
Income before income taxes | 1,174 | 1,210 | 2,468 | 2,580 | ||||||||||||
Income tax expense | (295 | ) | (285 | ) | (513 | ) | (592 | ) | ||||||||
Net income | $ | 879 | $ | 925 | $ | 1,955 | $ | 1,988 | ||||||||
Basic net income per share: | ||||||||||||||||
Net income | $ | 0.25 | $ | 0.25 | $ | 0.54 | $ | 0.54 | ||||||||
Diluted net income per share: | ||||||||||||||||
Net income | $ | 0.24 | $ | 0.25 | $ | 0.53 | $ | 0.53 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 3,574 | 3,657 | 3,595 | 3,654 | ||||||||||||
Diluted | 3,652 | 3,767 | 3,672 | 3,774 | ||||||||||||
Common shares outstanding | 3,554 | 3,642 | 3,554 | 3,642 | ||||||||||||
Contact:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
| Last Trade: | US$48.74 |
| Daily Change: | 2.39 5.16 |
| Daily Volume: | 64,599 |
| Market Cap: | US$158.890M |
September 05, 2024 November 02, 2023 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
